All In Biotech

Drug Trial Radar · NCT03698513

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

A Randomized, Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986177 (an Oral Antithrombotic) With Single and Dual Antiplatelet Therapy (Aspirin and Clopidogrel) in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Sep 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

113

Actual

Start

Oct 4, 2018

Primary completion

Feb 19, 2019

Study completion Feb 19, 2019

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will investigate the safety and interaction of BMS-986177 in healthy volunteers, when administered with Aspirin and/or Clopidogrel

Conditions

  • Healthy Volunteers

Interventions

  • BMS-986177Drug

    BMS-986177 capsule

  • Placebo (for BMS-986177)Other

    BMS-986177 placebo match capsule

  • ClopidogrelDrug

    Clopidogrel tablet

  • AspirinDrug

    Aspirin tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: Up to Day 33
  2. Incidence of Serious Adverse Events (SAEs)Time frame: Up to Day 95
  3. Incidence of Adverse Events (AEs) leading to discontinuationTime frame: Up to Day 33
  4. Number of participants with vital sign abnormalitiesTime frame: Up to Day 33
  5. Number of participants with 12-lead electrocardiogram (ECG) abnormalitiesTime frame: Up to Day 33
  6. Number of participants with clinical laboratory abnormalitiesTime frame: Up to Day 33
  7. Number of participants with physical examination abnormalitiesTime frame: Up to Day 33

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Development, LP

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.